Drugs / AMG 171
last change Sep 2021 re-read 3 minutes ago

AMG 171

Developed for
obesity disorder
Investigated by
Amgen

Trials 1

2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04199351 Dec 2019 → Sep 2021 obesity disorder Amgen Terminated No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AMG 171 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04199351 ↗